Downgrades Archives - Page 262 of 277

1 minute read

Morgan Stanley Downgrades Paramount Global to Underweight, Lowers Price Target to $22

July 18, 6:20 AM

Morgan Stanley analyst Benjamin Swinburne downgrades Paramount Global (NASDAQ:PARA) from Equal-Weight to Underweight and lowers the price target from $32 to $22.

PARA

1 minute read

Piper Sandler Downgrades Aeva Technologies to Neutral, Lowers Price Target to $3

By Benzinga Newsdesk

July 18, 6:13 AM

Piper Sandler analyst Arvind Ramnani downgrades Aeva Technologies (NYSE:AEVA) from Overweight to Neutral and lowers the price target from $5 to $3.

AEVA

1 minute read

Why This 10X Genomics Analyst Is Turning Bearish, Slashing Price Target

By Priya Nigam

July 15, 11:29 AM

10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenues Thursday that were meaningfully below the consensus estimates.

TXG

1 minute read

Maxim Group Downgrades Biotricity to Hold

By Benzinga Newsdesk

July 15, 9:43 AM

Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.

BTCY

1 minute read

B of A Securities Downgrades ProFrac Holding to Neutral, Announces $18 Price Target

By Benzinga Newsdesk

July 15, 8:21 AM

B of A Securities analyst Chase Mulvehill downgrades ProFrac Holding (NASDAQ:PFHC) from Buy to Neutral and announces $18 price target.

PFHC

1 minute read

B of A Securities Downgrades NexTier Oilfield to Neutral, Announces $9.5 Price Target

By Benzinga Newsdesk

July 15, 8:19 AM

B of A Securities analyst Chase Mulvehill downgrades NexTier Oilfield (NYSE:NEX) from Buy to Neutral and announces $9.5 price target.

NEX

1 minute read

B of A Securities Downgrades Patterson-UTI Energy to Neutral, Announces $13.5 Price Target

By Benzinga Newsdesk

July 15, 8:17 AM

B of A Securities analyst Chase Mulvehill downgrades Patterson-UTI Energy (NASDAQ:PTEN) from Buy to Neutral and announces $13.5 price target.

PTEN

1 minute read

B of A Securities Downgrades 10x Genomics to Underperform, Lowers Price Target to $35

By Benzinga Newsdesk

July 15, 8:15 AM

B of A Securities analyst Derik De Bruin downgrades 10x Genomics (NASDAQ:TXG) from Neutral to Underperform and lowers the price target from $80 to $35.

TXG

1 minute read

William Blair Downgrades 10x Genomics to Market Perform

By Benzinga Newsdesk

July 15, 7:09 AM

William Blair analyst Brian Weinstein downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Market Perform.

TXG

1 minute read

HC Wainwright & Co. Downgrades F-star Therapeutics to Neutral, Lowers Price Target to $7

By Benzinga Newsdesk

July 15, 6:18 AM

HC Wainwright & Co. analyst Patrick Trucchio downgrades F-star Therapeutics (NASDAQ:FSTX) from Buy to Neutral and lowers the price target from $35 to $7.

FSTX